November 9, 2017: The USPTO today published a patent application filed by Allergan, Inc. of Irvine, CA: U.S. Application Publication No. 2017/0320897, “Use of Agonists of Formyl Peptide Receptor 2 for Treating Ocular Inflammatory Diseases”.
According to the published abstract:
The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.
Published Claim 1 recites:
1. A method of treating an ocular inflammatory disease in a subject in need of such treatment, wherein the method comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one formyl peptide receptor 2 (FPR2) agonist to the subject;
wherein the ocular inflammatory disease is selected from the group consisting of uveitis, dry eye, keratitis, allergic eye disease, infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, retinitis, choroiditis, acute multifocal placoid pigment epitheliopathy, Behcet’s disease, post-surgical corneal wound healing, wet age-related macular degeneration (ARMD) and dry ARMD; and
wherein the agonist is a compound represented by Formula I, or a pharmaceutically acceptable salt thereof:
wherein: R1 is sec-butyl, C6-10 aryl, –CH2–(C6-10)aryl, –CH2-heterocycle, C4-8 cycloalkyl, C3-8 cycloalkenyl or heterocycle;
R2 is halogen or methyl;
R3 is halogen;
R4 is H, methyl or halogen;
R5 is OR6 or NH2;
and R6 is H or C2-4 alkyl;
or wherein the agonist is a compound selected from the group consisting of:
<19 other agonist compounds omitted>
and pharmaceutically acceptable salts thereof.
The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20170320897.
Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is simply a copy of the as-filed application, without examination.